诺和诺德减重药广告被指误导消费者，FDA发出警告

Core Viewpoint - The FDA issued a warning to Novo Nordisk regarding misleading advertisements for its oral weight loss drug semaglutide, amidst increasing competition in the weight loss drug market [3][4]. Group 1: FDA Warning and Advertising Issues - The FDA's warning letter indicates that Novo Nordisk's advertisements misleadingly suggest that semaglutide is more effective than other GLP-1 weight loss drugs, violating the Federal Food, Drug, and Cosmetic Act [3][4]. - The FDA requires Novo Nordisk to take immediate action to address the misleading information in its advertisements, including halting all misleading ads [4]. Group 2: Market Context and Competition - Approximately 12% of the U.S. population is currently using GLP-1 weight loss drugs, highlighting a significant market for these medications [3]. - Semaglutide became the first FDA-approved oral GLP-1 weight loss drug at the end of last year, ahead of competitors like Eli Lilly, and was officially launched in the U.S. earlier this year [3]. - Novo Nordisk faces challenges from competitors, including a lower-priced compounded generic version of semaglutide launched by Hims, which has negatively impacted Novo Nordisk's stock price [4]. - Eli Lilly's oral weight loss drug is expected to receive approval for market entry in April of this year, intensifying competition in the sector [5].